Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

population health screening

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

UPDATED: J&J expands US partnership for coronavirus treatments

Expands on exisiting alliance announced last week

- PMLiVE

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Hopes to extend the antibody drug conjugate's use into the earlier setting

- PMLiVE

This isn’t goodbye, it’s see you in August!

Bedrock Group imagines, creates and delivers industry-leading benefits

Bedrock Healthcare Communications

- PMLiVE

Novartis plans inclisiran trial in the UK

Swiss pharma also officially opens new London headquarters

- PMLiVE

A market-adapted agile approach to launch excellence

By Suzie Denton

- PMLiVE

It started with a miss

Is pharma finally heading for launch excellence?

Courageous Conversations ep.2: What Our Healthcare System Can Learn from AlphaGo

Impetus Digital

Courageous Conversations ep.1: Why Our Healthcare System is in Dire Need of Disruption

Impetus Digital

- PMLiVE

FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

KTE-X19 is also under regulatory review with the EMA

Novartis day

Novartis pulls ahead of Merck in MET-positive lung cancer race

FDA starts priority review of Swiss pharma's MET inhibitor

- PMLiVE

Exelixis bounces back with new prostate cancer data

Announces encouraging results after initial trial fail

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links